placeholder image
K. C. Demel All authors
About
Publications While At 开云体育
selected publications
Abstract
  • CT066 / 16 - Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53 [abstract]
    2024
  • Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with Pembrolizumab: clinical update [abstract]. 
    Journal of Clinical Oncology. 2024
    • presentations
    Contact
    full name
  • K. C. Demel
    • Quick Info
    Publications
    Publications in the past 10 years based solely on publications while at 开云体育. Publications in prior years appear in grey.
    Collaboration